Sangamo Therapeutics reports progress in gene therapies

Sangamo Therapeutics Reports Recent Business Highlights and ...

Pfizer plans to present detailed data from Phase 3 AFFINE trial evaluating giroctocogene fitelparvovec, an investigational Hemophilia A gene ...

Sangamo Therapeutics is aligning with the FDA on a regulatory pathway for its Fabry disease program, potentially accelerating approval by three ...

Sangamo Therapeutics Reports Recent Business Highlights and ...

Granted an exclusive license to Genentech for Sangamo's proprietary zinc finger repressors that are directed to the tau gene, which is ...

Investors & Media - Sangamo Therapeutics, Inc.

(Nasdaq: SGMO), a genomic medicine company, today announced the outcome of a recent successful interaction with the U.S. FDA, providing a clear ...

Sangamo Therapeutics, Inc. | Pioneering Genetic Cures

Sangamo uses a multi-platform approach to gene-based therapeutics with industry leading technologies in gene therapy, gene editing, cell therapy and gene ...

Sangamo Therapeutics Reports on Pfizer's Announcement of ...

Sangamo Therapeutics Reports on Pfizer's Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate.

Sangamo Therapeutics Reports Recent Business Highlights and ...

“We are pleased with the progress being made in business development discussions across our portfolio, including our Fabry disease program. We ...

Sangamo Therapeutics Reports Recent Business Highlights and ...

Continue to amass encouraging safety and efficacy data from the Phase 1/2 STAAR study of isaralgagene civaparvovec for Fabry disease, including ...

Pfizer Announces Positive Topline Results From Phase 3 Study of ...

Pfizer recently received FDA approval for BEQVEZ™ (fidanocogene elaparvovec), its hemophilia B gene therapy. BEQVEZ is also approved in Canada ...

Investors & Media - Sangamo Therapeutics, Inc.

Sangamo has granted Genentech an exclusive license to Sangamo's proprietary zinc finger repressors that are directed to the tau gene, which is ...

Sangamo Joins Companies Halting Sickle Cell Gene-edited Cell ...

Sangamo Joins Companies Halting Sickle Cell Gene-edited Cell Therapy Programs · 1. Sangamo Therapeutics reports recent business highlights and ...

Pfizer and Sangamo Therapeutics Announce Phase 3 Trial of ...

... gene therapy for patients with moderately severe to severe ... gene therapies for hemophilia A between Sangamo and Pfizer. In late ...

Sangamo Therapeutics Announces Q1 2024 Financial Results and ...

In a strategic move, Sangamo completed dosing in the Phase 1/2 STAAR study of isaralgagene civaparvovec for Fabry disease. The company is in ...

Sangamo Reports Early Progress in Pre-Clinical Hemophilia A ...

Both approaches have shown early success in lab mice with hemophilia A and non-human primates. New data from Sangamo's conventional gene therapy ...

Form 10-K for Sangamo Therapeutics INC filed 02/23/2023

Annual progress reports detailing ... research, development and commercialization of gene regulation therapies for the treatment of neurological diseases.

Genomic Medicine Clinical Trials - Sangamo Therapeutics, Inc.

We are conducting a Phase 1/2 clinical trial to evaluate the safety and tolerability of ST-920 gene therapy in Fabry disease. Program Details · Clinical Trial ...

Hemophilia A Gene Therapy Placed on Clinical Hold - CGTLive®

The FDA has placed Pfizer and Sangamo Therapeutics' phase 3 AFFINE study (NCT04370054) of giroctocogene fitelparvovec (SB-525; PF-07055480) for the potential ...

Clinical holds for cell and gene therapy trials: Risks, impact, and ...

The number of cell and gene therapy (CGT) clinical trials has increased sharply in the last several years; 10 years ago, approximately 1,800 ...

Sangamo Therapeutics Reports Recent Business Highlights and ...

Pfizer plans to present detailed data from Phase 3 AFFINE trial evaluating giroctocogene fitelparvovec, an investigational Hemophilia A gene ...

Gene therapy clinical trials worldwide to 2023—an update - Ginn

In October 2016, a patient with lung cancer became the first to be treated with CRISPR/Cas9 modified T cells in a Chinese clinical trial ( ...